CytomX Therapeutics, Inc.
Revenue Breakdown
| Fiscal Year | BMS | Pfizer | AbbVie | Amgen | Astellas | Regeneron | Moderna |
|---|---|---|---|---|---|---|---|
| FY2013 | $0 | $2.8M | $0 | $0 | $0 | $0 | $0 |
| FY2014 | $9.2M | $4.9M | $0 | $0 | $0 | $0 | $0 |
| FY2015 | $11.9M | $3.6M | $0 | $0 | $0 | $0 | $0 |
| FY2016 | $13.6M | $2.9M | $12.8M | $0 | $0 | $0 | $0 |
| FY2017 | $29.0M | $3.8M | $18.5M | $5.3M | $0 | $0 | $0 |
| FY2018 | $28.3M | $3.2M | $21.2M | $6.3M | $0 | $0 | $0 |
| FY2019 | $8.4M | $2.0M | $17.8M | $8.7M | $2.3M | $0 | $0 |
| FY2020 | $6.8M | $687.0K | $12.9M | $8.3M | $71.8M | $0 | $0 |
| FY2021 | $5.7M | $678.0K | $34.9M | $8.0M | $21.2M | $0 | $0 |
| FY2022 | $1.8M | $0 | $20.4M | $4.4M | $10.3M | $15.1M | $0 |
| FY2023 | $4.2M | $0 | $3.3M | $0 | $13.4M | $44.8M | $35.3M |